Edition:
United Kingdom

Alembic Pharmaceuticals Ltd (ALEM.NS)

ALEM.NS on National Stock Exchange of India

572.30INR
9:59am GMT
Change (% chg)

Rs17.50 (+3.15%)
Prev Close
Rs554.80
Open
Rs558.90
Day's High
Rs575.00
Day's Low
Rs550.55
Volume
136,644
Avg. Vol
82,458
52-wk High
Rs648.00
52-wk Low
Rs469.85

Chart for

About

Alembic Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged developing formulations and active pharmaceutical ingredients (API). The Company focuses on anti-infective, analgesic and, cough and cold therapies. It also focuses on therapies, such as cardiology, diabetes, gynecology, gastrointestinal,... (more)

Overall

Beta: 0.37
Market Cap(Mil.): Rs94,710.40
Shares Outstanding(Mil.): 188.52
Dividend: 4.00
Yield (%): 0.80

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-India's Alembic Pharmaceuticals Dec Qtr Consol PAT Rises

* DEC QUARTER CONSOL NET PAT 1.31 BILLION RUPEES VERSUS 843.9 MILLION RUPEES YEAR AGO

31 Jan 2018

BRIEF-Alembic Pharmaceuticals Says U.S. FDA Grants Orphan-Drug Designation To Rhizen Pharmaceuticals

* U.S. FDA GRANTS ORPHAN-DRUG DESIGNATION FOR TENALISIB TO RHIZEN PHARMACEUTICALS S.A. (RHIZEN) Source text - http://bit.ly/2C7DIYd Further company coverage:

26 Dec 2017

BRIEF-Alembic Pharma Gets U.S. FDA Nod For Generic Drug to Treat Overactive Bladder

* DRUG IS INTENDED TO TREAT OVERACTIVE BLADDER Source text: http://bit.ly/2BVyJWK Further company coverage:

12 Dec 2017

BRIEF-India's Alembic Pharma Sept-qtr consol PAT rises

* Says U.S. formulations business continues to face price erosion on some key products; India branded business showing signs of recovery‍​‍​

07 Nov 2017

BRIEF-Alembic Pharma buys generic drug developer Orit Laboratories

* Says ‍co buys U.S. based generic drug developer Orit Laboratories LLC​ Source text: http://bit.ly/2z3AKCI Further company coverage:

01 Nov 2017

BRIEF-Alembic Pharmaceuticals gets EU GMP certificate for audit conducted at Panelav

* Alembic Pharmaceuticals - gets EU GMP certificate for audit conducted at its formulation facility at Panelav from 8th to 10th Aug Source text for Eikon: Further company coverage:

31 Aug 2017

BRIEF-Alembic Pharma Ltd says sold Baddi plant to Scott Edil Pharmacia Ltd

* Says sold Baddi, Solan plant to Scott Edil Pharmacia Ltd on slump sale basis

23 Aug 2017

BRIEF-Alembic Pharmaceuticals sells formulations manufacturing facility at Baddi to Scott Edil Pharmacia

* Alembic pharmaceuticals says sold on slump sale basis its formulations manufacturing facility at Baddi, dist. Solan to Scott Edil Pharmacia Limited Source text for Eikon: Further company coverage:

23 Aug 2017

Earnings vs. Estimates